BR112016011583A2 - receptores de célula t humana de alta afinidade geneticamente modificados - Google Patents

receptores de célula t humana de alta afinidade geneticamente modificados

Info

Publication number
BR112016011583A2
BR112016011583A2 BR112016011583A BR112016011583A BR112016011583A2 BR 112016011583 A2 BR112016011583 A2 BR 112016011583A2 BR 112016011583 A BR112016011583 A BR 112016011583A BR 112016011583 A BR112016011583 A BR 112016011583A BR 112016011583 A2 BR112016011583 A2 BR 112016011583A2
Authority
BR
Brazil
Prior art keywords
genetically modified
high affinity
cell receptors
modified high
affinity human
Prior art date
Application number
BR112016011583A
Other languages
English (en)
Other versions
BR112016011583B1 (pt
Inventor
t harris Daniel
M Kranz David
N Smith Sheena
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112016011583A2 publication Critical patent/BR112016011583A2/pt
Publication of BR112016011583B1 publication Critical patent/BR112016011583B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112016011583-0A 2013-11-22 2014-11-21 Receptores de célula t humana de alta afinidade geneticamente modificados e seus usos BR112016011583B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
US61/907,887 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
BR112016011583A2 true BR112016011583A2 (pt) 2017-09-26
BR112016011583B1 BR112016011583B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
RU2016124163A (ru) 2017-12-27
WO2015077615A1 (en) 2015-05-28
SA516371174B1 (ar) 2019-04-14
CN105873945B (zh) 2020-07-17
ZA201603169B (en) 2020-05-27
AU2014352834B2 (en) 2019-08-29
SG10201804335QA (en) 2018-06-28
US20220396606A1 (en) 2022-12-15
CN105899530A (zh) 2016-08-24
IL245467B (en) 2020-04-30
PL3071593T3 (pl) 2019-11-29
RU2740648C2 (ru) 2021-01-19
KR20160085345A (ko) 2016-07-15
CA2930847A1 (en) 2015-05-28
MX2016006620A (es) 2017-05-11
CA2930852A1 (en) 2015-05-28
JP2020007374A (ja) 2020-01-16
US20190055298A1 (en) 2019-02-21
NZ719720A (en) 2020-09-25
KR20160087866A (ko) 2016-07-22
JP2022023196A (ja) 2022-02-07
RU2016124179A (ru) 2017-12-27
SG10201804330YA (en) 2018-07-30
AU2021202274A1 (en) 2021-05-06
MX2016006625A (es) 2016-12-02
EP3071594A4 (en) 2017-05-03
DK3071593T3 (da) 2019-06-11
AU2019272003B2 (en) 2021-05-06
PT3071593T (pt) 2019-06-27
TR201908404T4 (tr) 2019-07-22
EP3071593A1 (en) 2016-09-28
IL245467A0 (en) 2016-06-30
JP2017501129A (ja) 2017-01-12
MX371202B (es) 2020-01-22
EP3071594A1 (en) 2016-09-28
BR112016011567A2 (pt) 2017-10-24
CA2930852C (en) 2024-01-23
IL245468A0 (en) 2016-06-30
ES2729406T3 (es) 2019-11-04
MX2021006932A (es) 2021-07-07
AU2019272003A1 (en) 2019-12-19
AU2014352826B2 (en) 2019-08-01
JP2017501130A (ja) 2017-01-12
EP3071593A4 (en) 2017-05-03
AU2014352826A1 (en) 2016-05-26
US10344075B2 (en) 2019-07-09
US20160280756A1 (en) 2016-09-29
IL245468B (en) 2020-10-29
JP6970724B2 (ja) 2021-11-24
WO2015077607A1 (en) 2015-05-28
KR102415259B1 (ko) 2022-06-30
RU2729383C2 (ru) 2020-08-06
CN105873945A (zh) 2016-08-17
JP6697386B2 (ja) 2020-05-20
ZA201603116B (en) 2018-12-19
CN105899530B (zh) 2020-05-08
US20160280755A1 (en) 2016-09-29
EP3071593B1 (en) 2019-03-13
JP6476182B2 (ja) 2019-02-27
NZ719707A (en) 2020-09-25
AU2014352834A1 (en) 2016-05-26
US10023625B2 (en) 2018-07-17

Similar Documents

Publication Publication Date Title
BR112016011567A2 (pt) receptores de célula t humana de alta afinidade geneticamente modificados.
DK3071222T3 (da) Celle
DK3017520T3 (da) Solcelleanordning
SG11201510157YA (en) T cell receptors
ZA201600959B (en) T cell receptors
DK3587448T3 (da) Heterodimere proteiner
DK2941483T3 (da) Fremgangsmåde til at opnå immunstimulerende dendritriske celler
IL246572B (en) Examining an original application
CL2015002750A1 (es) Anticuerpos humanos pac1
FR3003076B1 (fr) Supercondensateur electrochimique
DK3234476T3 (da) Solfanger
FI20135397A (fi) Testausadapteri
DK3083944T3 (da) Pattedyrsmuskelafledte stamceller
DK3087076T3 (da) Imidazopyrazinonderivater
GB201322430D0 (en) T cell receptors
BR112016002552A2 (pt) rimel em gel
DK2821771T3 (da) Testfremgangsmåde
FR3009148B1 (fr) Preamplificateur de charge
BR112014021988A2 (pt) Estrutura de fixação de dispositivo de iluminação artificial
TH1501001472B (th) โครงสร้างช่องอัดประจุ
UA28899S (uk) Акумулятор
UA28818S (uk) Акумулятор
UA28816S (uk) Акумулятор
TH1401007645A (th) เซลล์แสงอาทิตย์ (Solar Cells)
UA28790S (uk) Батарея

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2014, OBSERVADAS AS CONDICOES LEGAIS